Summit Therapeutics Inc. (SMMT)
Market Cap | 2.63B |
Revenue (ttm) | n/a |
Net Income (ttm) | -614.93M |
Shares Out | 701.66M |
EPS (ttm) | -0.01 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,606,262 |
Open | 4.210 |
Previous Close | 3.750 |
Day's Range | 4.100 - 4.640 |
52-Week Range | 1.300 - 5.220 |
Beta | -1.21 |
Analysts | Strong Buy |
Price Target | 8.00 (+93.24%) |
Earnings Date | May 9, 2024 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes c... [Read more]
Analyst Forecast
According to one analyst, the rating for SMMT stock is "Strong Buy" and the 12-month stock price forecast is $8.0.
News
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bisp...
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecifi...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advis...
Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT
NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...
Lost Money on Summit Therapeutics Inc.(SMMT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...
Summit Therapeutics Being Investigated on Behalf of Summit Therapeutics Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...
Lost Money on Summit Therapeutics Inc.(SMMT)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global ...
Shareholders that lost money on Summit Therapeutics Inc.(SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...
Levi & Korsinsky Announces an Investigation on Behalf of Summit Therapeutics Inc. (SMMT) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...
Summit Therapeutics Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SMMT
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...
ATTENTION Summit Therapeutics Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...
SMMT ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Summit Therapeutics Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / February 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $SMMT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. (“Summi...
Levi & Korsinsky Reminds Shareholders of an Investigation into Summit Therapeutics Inc. (SMMT) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / February 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for ...
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
MIAMI, Fla.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financia...
Summit Therapeutics to Host Fourth Quarter & Full Year 2023
MIAMI, Fla.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financia...
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at Oppenheimer's 34th Annual Health...
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced substantial updates to the promising development of ivonescimab, as well as...
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 42nd Annual J.P...
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational prog...
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior ...
Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumo...
Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2023 financial result...